The central focus of the Cytogenetics Core (CYT) is to provide high quality cytogenetic and molecular cytogenetic analysis of human and animal model research samples. The CYT provides specialized services to members of the Mayo Clinic Cancer Center (MCCC) and other investigators within the Mayo research community. Services include: Cell Culture, Routine Chromosome Analysis, DNA and RNA fluorescence in situ Hybridization (FISH), Spectral Karyotyping (SKY) Analysis of human and mouse metaphases, and Custom DNA Probe Production. The service line has recently been enhanced through the development of an RNA FISH Probe Production line and a Tyramide Signal Amplification (TSA) protocol. Together, with the investigator, the CYT assists in determining how these techniques can be utilized to meet the evolving needs of their research studies. The CYT then assists in the translation of these novel assays toward employment as clinical diagnostic tests and prognostic markers of disease, as relevant. In addition to the test menu described above, the CYT staff also provides specialized training to investigators for FISH set-up, and microscope use in an effort to minimize investigator cost and economize technologist time. The technologists that make up the CYT have over 70 years of combined cytogenetic expertise. The CYT has a total of 99 users for this grant cycle, representing 10 of the 10 Cancer Center programs active at the time. Among our 99 users, 73 (74%) are Cancer Center members. Of these 73 investigators, 50 (68%) have active peer-reviewed funding. Many MCCC scientists at the forefront of genetic cancer research require both conventional and molecular cytogenetic techniques to advance their studies. The depth of knowledge and diverse expertise of the CYT staff provides an invaluable resource to investigators looking to move their research forward. Comprehensive cytogenetic and molecular cytogenetic testing and interpretation is not offered in any other core or research laboratory at Mayo Clinic. It is the CYT's deep commitment to working with the investigator to meet their unique scientific needs that enables the CYT to continue to be an invaluable resource to Mayo Clinic Cancer Center members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682936
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$37,049
Indirect Cost
$13,779
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944

Showing the most recent 10 out of 1129 publications